Retrospective Analyses of Systemic Chemotherapy and Cytoreductive Surgery for Patients with Ovarian Metastases from Colorectal Cancer: A Single-Center Experience

Oncology ◽  
2018 ◽  
Vol 95 (4) ◽  
pp. 220-228 ◽  
Author(s):  
Katsutoshi Sekine ◽  
Tetsuya Hamaguchi ◽  
Hirokazu Shoji ◽  
Atsuo Takashima ◽  
Yoshitaka Honma ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cytoreductive Surgery ◽  
Systemic Chemotherapy ◽  
Single Center ◽  
Ovarian Metastases ◽  
Single Center Experience

Retrospective analysis of the effects of systemic chemotherapy to the ovarian metastases from colorectal cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 731-731 ◽  
Author(s):  
Katsutoshi Sekine ◽  
Tetsuya Hamaguchi ◽  
Hirokazu Shoji ◽  
Shoko Nakamura ◽  
Takahiro Miyamoto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Surgical Resection ◽  
Cytoreductive Surgery ◽  
Systemic Chemotherapy ◽  
Palliative Chemotherapy ◽  
Objective Response ◽  
First Line ◽  
Ovarian Metastases ◽  
Third Line ◽  
Metastatic Sites

731 Background: Ovarian metastases from colorectal cancers are relatively rare. Since most ovarian metastases are also associated with other metastatic sites, the prognosis is reported to be poor. It is not fully understood whether the response to systemic chemotherapy of ovarian metastases differs from that to other metastatic sites. Methods: We retrospectively reviewed the clinical data of patients with ovarian metastases from colorectal cancer treated at our hospital between January 2006 and December 2015. Results: Among the 635 female patients with relapsed or metastatic colorectal cancer, 57 (9.0%) had ovarian metastases before the first-line treatment; 37 patients received palliative chemotherapy, and 20 patients were initially treated by surgical resection. In addition, 38 cases of ovarian metastases developed after the initiation of first-line chemotherapy. Overall, 95 patients (15.0%) with ovarian metastases were treated during this period. The objective response rate for systemic chemotherapy of ovarian metastases was lower than that for other metastatic sites (22.9 % vs 60.9 % for first-line, 3.4 % vs 13.6 % for second-line, 11.1 % vs 26.6 % for third-line, and 0% vs 18.2 % for fourth-line, respectively). After the initiation of chemotherapy, surgical resection of ovarian metastases was positively associated with a longer overall survival (26.8 months for cytoreductive surgery and 17.0 months for only systemic chemotherapy, p < 0.001), especially when the other metastatic sites had not progressed after chemotherapy. Conclusions: Ovarian metastases are less responsive to systemic chemotherapy compared to the extra-ovarian metastases. Our data also suggest that multi-disciplinary treatment strategy including systemic chemotherapy and cytoreductive surgery might improve the prognosis of ovarian metastases.

Laparoscopic staged colon‐first resection for metastatic colorectal cancer: Perioperative and midterm outcomes from a single‐center experience

2020 ◽  
Vol 122 (7) ◽  
pp. 1453-1461
Author(s):  
Juan Carlos Sebastián‐Tomás ◽  
Carlos Domingo‐del Pozo ◽  
Segundo Ángel Gómez‐Abril ◽  
Sergio Navarro‐Martínez ◽  
Inmaculada Ortiz‐Tarín ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Single Center ◽  
Single Center Experience
Sign in / Sign up

Export Citation Format

Share Document